Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Other Accumulated Expenses (2020 - 2025)

Janux Therapeutics (JANX) has disclosed Other Accumulated Expenses for 6 consecutive years, with $944000.0 as the latest value for Q4 2025.

  • Quarterly Other Accumulated Expenses rose 2.83% to $944000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $944000.0 through Dec 2025, up 2.83% year-over-year, with the annual reading at $944000.0 for FY2025, 2.83% up from the prior year.
  • Other Accumulated Expenses for Q4 2025 was $944000.0 at Janux Therapeutics, up from $551000.0 in the prior quarter.
  • The five-year high for Other Accumulated Expenses was $1.0 million in Q2 2023, with the low at $199000.0 in Q2 2021.
  • Average Other Accumulated Expenses over 5 years is $644473.7, with a median of $609000.0 recorded in 2022.
  • The sharpest move saw Other Accumulated Expenses skyrocketed 194.52% in 2023, then fell 29.75% in 2024.
  • Over 5 years, Other Accumulated Expenses stood at $478000.0 in 2021, then skyrocketed by 30.33% to $623000.0 in 2022, then fell by 11.88% to $549000.0 in 2023, then skyrocketed by 67.21% to $918000.0 in 2024, then grew by 2.83% to $944000.0 in 2025.
  • According to Business Quant data, Other Accumulated Expenses over the past three periods came in at $944000.0, $551000.0, and $587000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.